Form 4: Avidity Biosciences Director Noreen Henig Reports Stock Option Grant

Director Noreen Henig reports the acquisition of stock options in Avidity Biosciences.

Summary

• On June 13, 2024, Noreen Henig, a director of Avidity Biosciences, Inc., was granted stock options to purchase 13,489 shares of common stock.
• The exercise price of the stock options is $39.96.
• The options vest on the earlier of the first anniversary of the grant date or the next annual meeting of the Issuer's stockholders, contingent upon continuous service on the board.
• The expiration date for these options is June 12, 2034.
• Following the transaction, Noreen Henig directly owns 13,489 derivative securities.

Sentiment

Score: 7

Explanation: The document indicates standard compensation practices. The grant of stock options is generally viewed positively as it aligns the director's interests with those of the shareholders.

Positives

• The grant of stock options to a director aligns their interests with those of the shareholders, incentivizing them to work towards the company's success.

Industry Context

Stock option grants are a common practice in the biotechnology industry to incentivize and retain key personnel, aligning their interests with the long-term success of the company.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for directors in publicly traded biotechnology companies.
• The vesting schedule and exercise price are typical for such grants, aligning with industry norms for incentivizing long-term performance.

Stakeholder Impact

• The stock option grant could have a minor positive impact on shareholder sentiment as it aligns director interests with company performance.

Key Dates